IMX-110 in Soft Tissue Sarcoma vs. Standards of Care

Experiment # 1356

1. Description

a. How does IMX-110 compare to soft tissue sarcoma standards of care?

2. Disease Description

STS is a rare cancer that begins in the tissues that connect, support, and surround the body structures. These tissues include muscle, fat, blood vessels, tendons, nerves and joint linings. The global STS market is estimated to reach approximately $6.5 billion by 2030 from the estimated $2.9 billion in 2019. Globally, there are roughly 116,000 new cases of STSs each year, of which 21,500 are in the European Union and 40,500 are in China. According to the American Cancer Society, there were roughly 13,000 new cases of STS in the United States during 2020. Approximately 160,000 people live with soft tissue cancers in the United States.

3. Animal Model Description

a. We are conducting a pre-clinical study in a SW 872 mouse model. The primary endpoint of the study is tumor growth inhibition as measured by tumor volume, with the secondary endpoint being overall survival. Mice bearing SW872 cell line tumors are treated with one cycle of drug. Tumor size will be measured at regular intervals, animal well -being assessed.

4. Primary Experimental Groups

a. Placebo

b. IMX-110

c. FDA-approved sarcoma drugs

5. Ongoing Experimental Updates Display – Select Data / Monthly Updates

a. Dashboard as of [X] Day

i. Include Placebo, IMX-110, Free DOX

SWIPE charts to see more